Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.27)
# 3,546
Out of 4,945 analysts
78
Total ratings
39.51%
Success rate
-17.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $203 | $194.66 | +4.28% | 19 | Aug 8, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $5.57 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $7.53 | - | 11 | Jun 26, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $35.88 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.40 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.14 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.11 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.66 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $24.05 | - | 2 | Jan 13, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $10.19 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $8.52 | +134.74% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.50 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.76 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.03 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.59 | +88.68% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $8.60 | +2,459.57% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.11 | +352.49% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.37 | +1,506.77% | 1 | Aug 12, 2022 |
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $200 → $203
Current: $194.66
Upside: +4.28%
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $5.57
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.53
Upside: -
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $35.88
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.40
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.14
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.11
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.66
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $24.05
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.19
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $8.52
Upside: +134.74%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.50
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.76
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.03
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.59
Upside: +88.68%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $8.60
Upside: +2,459.57%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.11
Upside: +352.49%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.37
Upside: +1,506.77%